Histone Deacetylase Inhibition Overcomes Drug Resistance through a miRNA-Dependent Mechanism

1Oncology, Johns Hopkins University School of Medicine.
Molecular Cancer Therapeutics (Impact Factor: 5.68). 08/2013; 12(10). DOI: 10.1158/1535-7163.MCT-13-0418
Source: PubMed


The treatment of specific tumor cell lines with poly- and oligoamine analogues results in a super-induction of polyamine catabolism that is associated with cytotoxicity; however, other tumor cells demonstrate resistance to analogue treatment. Recent data indicate that some of these analogues also have direct epigenetic effects. We therefore sought to determine the effects of combining specific analogues with an epigenetic targeting agent in phenotypically resistant human lung cancer cell lines. We demonstrate that the histone deacetylase inhibitor MS-275 when combined with (N1, N11)-bisethylnorspermine (BENSpm) or (N1, N12)-bis(ethyl)-cis-6,7-dehydrospermine tetrahydrochloride (PG-11047) synergistically induces the polyamine catabolic enzyme spermidine/spermine N1-acetyltransferase (SSAT), a major determinant of sensitivity to the antitumor analogues. Evidence indicates that the mechanism of this synergy includes reactivation of miR-200a, which targets and destabilizes kelch-like ECH-associated protein 1 (KEAP1) mRNA, resulting in the translocation and binding of nuclear factor (erythroid-derived 2)-like 2 (NRF2) to the polyamine-responsive element of the SSAT promoter. This transcriptional stimulation combined with positive regulation of SSAT mRNA and protein by the analogues results in decreased intracellular concentrations of natural polyamines and growth inhibition. The finding that an epigenetic targeting agent is capable of inducing a rate-limiting step in polyamine catabolism to overcome resistance to the antitumor analogues represents a completely novel chemotherapeutic approach. This is also the first demonstration of miRNA-mediated regulation of the polyamine catabolic pathway. Furthermore, the individual agents used in this study have been investigated clinically; therefore, translation of these combinations into the clinical setting holds promise.

Download full-text


Available from: Patrick M. Woster, Oct 09, 2015
1 Follower
48 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The NRF2 transcription factor (nuclear factor-erythroid 2 p45-related factor 2) has been identified as a key molecular player in orchestrating adaptive cellular interactions following a wide spectrum of cellular stress conditions that could be either extracellular or intracellular. Dysregulation of the NRF2 system is implicated in various disease states, including inflammatory conditions. The NRF2 transcription factor is also known to permit cross talk with several other essential cellular signaling pathways. Recent literature has also elucidated the potential influences of miRNA activity over modulations of the NRF2 signalling network. Consequently, further delving into the knowledge regarding the extent of miRNA-induced epigenetic gene regulatory control on key elements of the NRF2 signalling pathway and its cross talk, particularly within the context of cancer models, can prove to be of high clinical importance. This is so since such miRNAs, once identified and validated, can be potentially exploited as novel drug targets for emerging translational medicine-based therapies.
    Journal of nucleic acids 08/2015; 2015(8):1. DOI:10.1155/2015/143636
  • [Show abstract] [Hide abstract]
    ABSTRACT: Preclinical Research Chromatin-modifying drugs, such as histone deacetylase inhibitors (HDACi), have shown potential as cancer therapeutics, either alone or in combination with other therapies. HDACi have the ability to reverse aberrant epigenetic modifications associated with cancer, namely dysregulated histone acetylation. There are currently three FDA approved HDACi; vorinostat, romidepsin, and panobinostat. Epigenetic modifications can regulate the expression of protein coding genes, and in addition can alter expression of microRNA (miRNA) genes. Many miRNAs play key roles in cell proliferation and apoptosis, and are commonly dysregulated in cancer states. A number of in vitro and in vivo studies have demonstrated the ability of chromatin-modifying drugs to alter miRNA expression, which may provide the basis for further investigation of miRNAs as therapeutic targets or as biomarkers of drug response. This review summarises findings from studies investigating the effects of HDACi on miRNA expression, as well as key clinical trials involving HDACi. Understanding how chromatin-modifying drugs epigenetically modulate miRNA genes provides further insight into the cellular mechanisms that deliver therapeutic responses, and may assist in refining treatment strategies. Drug Dev Res, 2015. © 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.
    Drug Development Research 08/2015; 76(6). DOI:10.1002/ddr.21268 · 0.77 Impact Factor